Edgewise Therapeutics Stock Market Value
| EWTX Stock | USD 31.98 0.03 0.09% |
| Symbol | Edgewise |
Edgewise Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edgewise Therapeutics. If investors know Edgewise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edgewise Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Return On Assets (0.22) | Return On Equity (0.32) |
The market value of Edgewise Therapeutics is measured differently than its book value, which is the value of Edgewise that is recorded on the company's balance sheet. Investors also form their own opinion of Edgewise Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Edgewise Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edgewise Therapeutics' market value can be influenced by many factors that don't directly affect Edgewise Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edgewise Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edgewise Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edgewise Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Edgewise Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Edgewise Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Edgewise Therapeutics.
| 05/26/2024 |
| 11/22/2024 |
If you would invest 0.00 in Edgewise Therapeutics on May 26, 2024 and sell it all today you would earn a total of 0.00 from holding Edgewise Therapeutics or generate 0.0% return on investment in Edgewise Therapeutics over 180 days. Edgewise Therapeutics is related to or competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, Transcode Therapeutics, and Quoin Pharmaceuticals. Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases More
Edgewise Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Edgewise Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Edgewise Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.63 | |||
| Information Ratio | 0.1138 | |||
| Maximum Drawdown | 61.02 | |||
| Value At Risk | (5.51) | |||
| Potential Upside | 6.65 |
Edgewise Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edgewise Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Edgewise Therapeutics' standard deviation. In reality, there are many statistical measures that can use Edgewise Therapeutics historical prices to predict the future Edgewise Therapeutics' volatility.| Risk Adjusted Performance | 0.1041 | |||
| Jensen Alpha | 0.6967 | |||
| Total Risk Alpha | 0.0884 | |||
| Sortino Ratio | 0.239 | |||
| Treynor Ratio | 0.317 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Edgewise Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Edgewise Therapeutics Backtested Returns
Edgewise Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Edgewise Therapeutics secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13% return per unit of risk over the last 3 months. By reviewing Edgewise Therapeutics' technical indicators, you can evaluate if the expected return of 0.97% is justified by implied risk. Please utilize Edgewise Therapeutics' Coefficient Of Variation of 791.97, downside deviation of 3.63, and Mean Deviation of 3.71 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Edgewise Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 3.01, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Edgewise Therapeutics will likely underperform. Please check Edgewise Therapeutics' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether Edgewise Therapeutics' price patterns will revert.
Auto-correlation | 0.25 |
Poor predictability
Edgewise Therapeutics has poor predictability. Overlapping area represents the amount of predictability between Edgewise Therapeutics time series from 26th of May 2024 to 24th of August 2024 and 24th of August 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Edgewise Therapeutics price movement. The serial correlation of 0.25 indicates that over 25.0% of current Edgewise Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.25 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 45.01 |
Edgewise Therapeutics lagged returns against current returns
Autocorrelation, which is Edgewise Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Edgewise Therapeutics' stock expected returns. We can calculate the autocorrelation of Edgewise Therapeutics returns to help us make a trade decision. For example, suppose you find that Edgewise Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Edgewise Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Edgewise Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Edgewise Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Edgewise Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Edgewise Therapeutics Lagged Returns
When evaluating Edgewise Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Edgewise Therapeutics stock have on its future price. Edgewise Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Edgewise Therapeutics autocorrelation shows the relationship between Edgewise Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Edgewise Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.